GF:ECX Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer, which relies on its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer. Its development pipeline also contains tests for screening, monitoring, diagnosis, and prognosis assessment in colorectal and lung cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol EPGNF.

This company has ADRs that trade in the U.S. as the symbol EPGNY.This company has cross-listed shares that trade in the U.S. as the symbol EPGNF.

0.38 EUR
As of 12/23/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Diagnostics & Research
Index country:  Germany
Country of incorporation:  Germany
IPO date:  01/01/1900
Stock exchange:    Frankfurt Stock Exchange
Exchange country:   Germany
Market cap:   8,113,220 EUR
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy